StockNews.com began coverage on shares of AngioDynamics (NASDAQ:ANGO – Free Report) in a report published on Thursday morning. The brokerage issued a hold rating on the medical instruments supplier’s stock. Several other research analysts have also recently issued reports on the company. Canaccord Genuity Group reduced their price objective on AngioDynamics from $20.00 to $17.00 […]
AngioDynamics, Inc. (NASDAQ:ANGO – Get Free Report) was the recipient of a significant increase in short interest in the month of September. As of September 15th, there was short interest totalling 1,850,000 shares, an increase of 51.6% from the August 31st total of 1,220,000 shares. Based on an average daily volume of 650,100 shares, the […]
AngioDynamics, Inc. (NASDAQ:ANGO – Free Report) – Stock analysts at Zacks Research dropped their Q4 2025 earnings per share estimates for AngioDynamics in a research note issued on Tuesday, September 12th. Zacks Research analyst D. Dey now anticipates that the medical instruments supplier will post earnings per share of $0.00 for the quarter, down from […]
AngioDynamics (NASDAQ:ANGO – Get Free Report) and Carmell Therapeutics (NASDAQ:CTCX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, earnings, profitability and institutional ownership. Analyst Recommendations This is a summary of recent […]
AngioDynamics (NASDAQ:ANGO – Get Free Report) and Carmell Therapeutics (NASDAQ:CTCX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends. Insider and Institutional Ownership 90.5% of AngioDynamics shares […]